Abstract
Metastasis is the primary cause of mortality in patients with breast cancer and lacks effective therapeutic agents. Oridonin, an active diterpenoid compound isolated from Rabdosia rubescens, was identified to be the most potent anti-tumor ingredient. However, the molecular mechanisms responsible for its anti-metastatic effects remain unclear. In the present study, oridonin significantly suppressed the migration, invasion and adhesion of MDA-MB-231 and 4T1 breast cancer cells, and inhibited tube formation of human umbilical vein endothelial cells in a dose-dependent manner. The expression levels of epithelial-mesenchymal transition (EMT)-associated marker and the hypoxia inducible factor 1α (HIF-1α)/vascular endothelium growth factor (VEGF) signaling pathway mRNA and proteins were determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively in vitro. The results demonstrated that oridonin effectively inhibited EMT as demonstrated by the significant increases in the expression levels of E-cadherin, and decreased expression of N-cadherin, Vimentin and Snail. In addition, oridonin exerted its anti-angiogenesis activity through significantly decreasing HIF-1α, VEGF-A and VEGF receptor...Continue Reading
References
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 10, 2003·International Journal of Oncology·Takayuki IkezoeH Phillip Koeffler
Sep 16, 2010·Cancer Cell International·Yupei Li, Deni S Galileo
Oct 19, 2012·Oncology Reports·Tao HuangLiping Fang
May 25, 2013·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Zechun KangShuping Zhang
Jun 12, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hua LiuZhiyong Shen
Jun 14, 2014·Microvascular Research·Flávia Cristine Mascia LopesNicola Conran
Dec 9, 2014·PloS One·Yanmin DongZhengfang Yi
Jun 6, 2015·PloS One·Lamis YehiaMarwan El-Sabban
Jun 7, 2015·Cancer Letters·Jin-Mei YuZhuo-Wei Hu
Aug 28, 2015·SpringerPlus·Matthew T CookSalman M Hyder
Sep 24, 2015·Biochemical and Biophysical Research Communications·Chao ShaoFeihai Ling
Nov 26, 2015·Journal of Thrombosis and Haemostasis : JTH·X Y CuiP M Sandset
Dec 18, 2015·International Journal of Oncology·Li-Xu YanJie Chen
Feb 6, 2016·Oncotarget·Yanan ZhangQinong Ye
Feb 16, 2016·Scientific Reports·Panseon KoSangmyung Rhee
Nov 12, 2016·Cancer Letters·Shuwei LiangHongsheng Wang
Dec 9, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Huiling ChenJunming Guo
Feb 13, 2017·Archives of Gynecology and Obstetrics·Magdalena MatysiakMarcin Kruszewski
May 24, 2017·Oncology Reports·Eryun ZhangZhengtao Wang
Jun 6, 2017·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Shixin XiaHonglian Guan
Jun 13, 2017·Nature Communications·Deepika NeelakantanHeide L Ford
Jun 29, 2017·International Journal of Oncology·Dong Hwan KimNam Deuk Kim
Jul 26, 2017·Cellular Oncology (Dordrecht)·Katayoon PakravanMohammad Javan
Aug 7, 2017·Oncology Letters·Zhongwei HeYing Liu
Sep 12, 2017·Drug Delivery·Thiruganesh RamasamyJong Oh Kim
Oct 13, 2017·Cancer Letters·Eun Jung SohnSung-Hoon Kim
Oct 19, 2017·Oncology Reports·Tao ZhouHongyuan Li
Oct 20, 2017·Oncology Reports·Jiaqiang AnYan Gao
Dec 30, 2017·Oncology Reports·Hui HuTingtao Chen
Citations
Jan 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yuanyuan ZhangHuagang Sheng
Mar 14, 2020·Journal of Cellular and Molecular Medicine·Linhao XuJian Chen
Jul 3, 2020·Biological & Pharmaceutical Bulletin·Qiong YangShuguang Li
Jul 13, 2019·Frontiers in Pharmacology·Ming HongYibin Feng
Feb 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nurul Akmaryanti AbdullahNoraina Muhamad Zakuan
Nov 26, 2020·Drug Design, Development and Therapy·Ruo-Lan LiChun-Jie Wu